Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

Related Keywords

,Optimizing Outcomes ,Patients With ,Translating Evidence ,Clinical Practice ,Metastatic Renal Cell ,Renal Cell Carcinoma ,Nrcc ,Kidney Cancer ,Metastatic Rcc ,Metastatic Kidney Cancer ,Advanced Rcc ,Advanced Kidney Cancer ,Intermediate Risk ,Poor Risk ,Ipi Nivo ,Nivo Ipi ,Nivolumab ,Ipilimumab ,Trio Therapy ,Immune Checkpoint Inhibitors ,Checkmate 214 ,Novel Therapy ,Combination Therapy ,Overall Survival Data ,Taos Data ,Duration Of Response ,Adverse Events ,Drug Adverse Events ,Quality Of Life ,Rqol ,